Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

The Best Treatment Option After Surgery for Triple-Negative Breast Cancer

The Best Treatment Option After Surgery for Triple-Negative Breast Cancer

Triple-negative breast cancer is distinguished by the absence of estrogen receptors (ER) and progesterone receptors (PR) on cancer cell surfaces, and the absence of overexpression of HER2 receptors. It is a subtype of breast cancer and accounts for around 15% of all breast cancers. Compared with other breast cancers, it tends to divide, multiply and metastasize more quickly, and is therefore more sensitive to chemotherapy. In addition, around 11% of triple-negative breast cancers are associated with hereditary cancer genes (BRCA 1-2) and tend to occur at younger ages. 

If triple-negative breast cancer is detected early, the standard treatment is surgery followed by adjuvant (protective) chemotherapy. On August 13, 2020, JAMA Oncology published a comprehensive study called PATTERN, according to which the best adjuvant treatment for this cancer appears to be the carboplatin plus paclitaxel combination chemotherapy regimen.

This randomized (random patient enrollment) phase-III clinical trial was conducted at multiple centers in China.

Why the study matters

The GeparSixto and CALGB 40603 studies had previously demonstrated the effectiveness of platinum chemotherapy drugs in neoadjuvant (preoperative) and palliative (advanced-stage) treatment of patients with triple-negative breast cancer, and they had entered routine practice with recommendations from international guidelines. PATTERN is the first study to clearly demonstrate the adjuvant effectiveness of platinum chemotherapy drugs and produce data with a high potential to change clinical practice in guidelines.

Study details

  • Patients were enrolled between July 2011 - April 2016.
  • The median follow-up period was 62 months.
  • The study inclusion criteria were:
    • being a woman aged 18-70,
    • having operable triple-negative breast cancer and not having previously received neoadjuvant chemotherapy,
    • having axillary lymph node metastases detected during surgery or a tumor larger than 1 cm,
    • an overall performance score of 0-1,
    • and adequate blood, kidney and liver values.

Results

  • The study enrolled 647 patients who met the criteria above. 325 patients entered the "6 cycles of carboplatin-paclitaxel" arm; 322 patients entered the "3 cycles of FEC, 3 cycles of docetaxel" arm.
  • There were no deaths due to chemotherapy side effects in either arm. The groups did not differ in chemotherapy completion rates or the need for dose reduction.
  • In terms of rates of regional and distant metastasis or recurrence (cancer returning), the carboplatin-paklıtaksel arm was significantly superior to the standard chemotherapy arm, FEC-docetaxel.
  • The 5-year disease-free survival rates were 86.5% in the carboplatin-paklitasel arm and 80.5% in the FEC-docetaxel arm. Carboplatin-paklitasel was found to reduce the risk of recurrence/metastasis by 35% compared with standard treatment.
  • The 5-year overall survival rate was 93.4% in the carboplatin-paklitasel arm and 89.8% in the FEC-docetaxel arm.

In conclusion, these data strongly support platinum chemotherapy becoming standard in the adjuvant treatment of triple-negative breast cancer as well, and are of a nature to change clinical practice.

Sources

Ke-Da Yu; Fu-Gui Ye; Min He et al.
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer
A Phase 3 Randomized Clinical Trial.
JAMA Oncol. Published online August 13, 2020.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

The Best Treatment Option After Surgery for Triple-Negative Breast Cancer

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy